Table 4.

Variants of Interest: Mutations and key features.

Pango Lineage/First Detected/WHO Classification	Spike Protein Substitution	Total Mutations	Key Features
B.1.525 UK/Nigeria ETA (WHO)	A67V, del69, del70, del144, E484K, D614G, Q677H, F888L	L5F, T95I, D253G, S477N, A701V ORF1a-nsp2: T85I ORF1a-nsp4: L438P ORF1a-nsp6: 9bp deletion, delta106–108. ORF1b-nsp12: P323L ORF1b-nsp13: Q88H ORF3a: Q57H N: P199L, M234I	✓ Potential decreased neutralization by some monoclonal antibody treatment and by convalescent and vaccine sera [116]
B.1.526 New York, United States IOTA (WHO)	Receptor-binding domain: E484K, S477N Spike: L5F, T95I NTD: D253G Carboxy(C)-terminal region of the S1 domain: D614G S2 subunit: A701V.	A16500C, A22320G, T9867C	✓ Decreased susceptibility to monoclonal antibody treatments [116] ✓ Decreased neutralization by convalescent and vaccine sera [116]
B.1.617.1 India KAPPA (WHO)	T95I, G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H.		✓ Potential decrease in neutralization by some monoclonal antibody treatment and by vaccine sera [142]
B.1.617.3 India	T19R, G142D, L452R, E484Q, D614G, P681R, D950N		✓ Potential decrease in neutralization by some monoclonal antibody treatment and by vaccine sera [142]